Literature DB >> 22183851

Type-specific human papillomavirus infections among young heterosexual male and female STI clinic attendees.

Henrike J Vriend1, Hein J Boot, Marianne A B van der Sande.   

Abstract

BACKGROUND: Baseline genotype-specific human papillomavirus (HPV) prevalence rates and associated risk factors per gender enable future assessment of the impact of vaccination on HPV dynamics.
METHODS: Before the start of national HPV vaccination for girls, data were collected cross-sectionally in nationwide Dutch sexually transmitted infections (STI) clinics among heterosexual males (n = 430) and females (n = 1136) aged 16 to 24 years. Self-collected vaginal or penile swabs were analyzed by a sensitive polymerase chain reaction (SPF10) and genotyped with line probe assay. Logistic regression was applied to estimate determinants of HPV prevalent infections.
RESULTS: HPV prevalence was 54% among males and 72% among females. High-risk (HR) HPV was present in males and females, 40% and 58%, respectively. Independent risk factors for HR-HPV infection were female gender, number of lifetime sex partners and a history of chlamydia or gonorrhea. In addition, not having a casual partner and consistent condom use were protective factors in women, but not in men. For low-risk (LR) HPV, the odds were smaller. Multiple HR-HPV and sexual risk behavior showed a stronger association compared with a single HR-HPV infection.
CONCLUSIONS: Prevalence of HR-HPV is high in both genders. Infection with multiple HR-HPV types was more associated with high-risk sexual behavior than infection with LR-HPV types or a single HR-HPV type.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22183851     DOI: 10.1097/OLQ.0b013e318235b3b0

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  9 in total

1.  High-risk human papillomavirus prevalence is associated with HIV infection among heterosexual men in Rakai, Uganda.

Authors:  Aaron A R Tobian; Mary K Grabowski; Godfrey Kigozi; Patti E Gravitt; Kevin P Eaton; David Serwadda; Fred Nalugoda; Maria J Wawer; Thomas C Quinn; Ronald H Gray
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

2.  Association of Chlamydia trachomatis infection and herpes simplex virus type 2 serostatus with genital human papillomavirus infection in men: the HPV in men study.

Authors:  Catharina Johanna Alberts; Maarten F Schim van der Loeff; Mary R Papenfuss; Roberto José Carvalho da Silva; Luisa Lina Villa; Eduardo Lazcano-Ponce; Alan G Nyitray; Anna R Giuliano
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

3.  Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.

Authors:  Petra J Woestenberg; Audrey J King; Birgit H B van Benthem; Robine Donken; Suzan Leussink; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Christian J P A Hoebe; Johannes A Bogaards
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

4.  Study protocol of the iMPaCT project: a longitudinal cohort study assessing psychological determinants, sexual behaviour and chlamydia (re)infections in heterosexual STI clinic visitors.

Authors:  Daphne A van Wees; Janneke C M Heijne; Titia Heijman; Karlijn C J G Kampman; Karin Westra; Anne de Vries; Mirjam E E Kretzschmar; Chantal den Daas
Journal:  BMC Infect Dis       Date:  2018-11-13       Impact factor: 3.090

5.  Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.

Authors:  Petra J Woestenberg; Johannes A Bogaards; Audrey J King; Suzan Leussink; Marianne Ab van der Sande; Christian Jpa Hoebe; Birgit Hb van Benthem
Journal:  Int J Cancer       Date:  2018-12-21       Impact factor: 7.396

6.  Evidence for Missing Positive Results for Human Papilloma Virus 45 (HPV-45) and HPV-59 with the SPF10-DEIA-LiPA25 (Version 1) Platform Compared to Type-Specific Real-Time Quantitative PCR Assays and Impact on Vaccine Effectiveness Estimates.

Authors:  Kahren van Eer; Suzan Leussink; Tim T Severs; Naomi van Marm-Wattimena; Petra J Woestenberg; Johannes A Bogaards; Audrey J King
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

7.  Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.

Authors:  Henrike J Vriend; Johannes A Bogaards; Fiona R M van der Klis; Mirte Scherpenisse; Hein J Boot; Audrey J King; Marianne A B van der Sande
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands.

Authors:  Audrey J King; Jan A Sonsma; Henrike J Vriend; Marianne A B van der Sande; Mariet C Feltkamp; Hein J Boot; Marion P G Koopmans
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

9.  Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.

Authors:  Joske Hoes; Petra J Woestenberg; Johannes A Bogaards; Audrey J King; Hester E de Melker; Johannes Berkhof; Christian J P A Hoebe; Marianne A B van der Sande; Birgit H B van Benthem
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.